Suppressing the expression of a protein called ataxin-2 may prolong survival in patients with amyotrophic lateral sclerosis (ALS), according to a recent mouse study.
The study, “Therapeutic Reduction Of Ataxin-2 Extends Lifespan And Reduces Pathology In TDP-43 Mice,” was published in the journal Nature.
According to researchers, nearly all ALS patients have aggregates of a protein called TDP-43 in their brains and spinal cords, and rare mutations in the gene encoding this protein can trigger ALS. However, TDP-43 cannot be eliminated in neurons because it plays several important functions in neuronal survival.
A research team led by Aaron Gitler, PhD, from the Stanford University School of Medicine, developed a way to fight the toxic effect of TDP-43 aggregates without completely eliminating the protein from the brain.
Their work was based on previous findings that when the protein ataxin-2 is absent, it helped neurons survive in the presence of human TDP-43 aggregates in yeast and flies, and that the human form of ataxin-2, which is more stable and lasts longer in neurons, increased the risk of ALS. Researchers then hypothesized that reducing ataxin-2 levels could protect neurons in ALS.
They tested their idea using genetically altered mice that produce high levels of the human TDP-43 protein, that present symptoms resembling human ALS, and live no more than one month. These animals were then altered to have half the normal amount of ataxin-2, or none at all.
The decrease in ataxin-2 reduced aggregation of TDP-43 markedly increased survival and improved motor function in the mice.
“But what was really astounding,” Lindsay Becker, study’s first author, said in a press release, “was that when we completely removed ataxin-2, there was really an unprecedented survival; some of the mice lived hundreds and hundreds of days.”
The team then used a more therapeutically applicable approach to target ataxin-2. They administered antisense oligonucleotides (ASOs, tiny molecules that block the expression of specific proteins) against ataxin-2 to TDP-43 mice, and observed that a single treatment markedly extended survival.
Together, these results suggest that targeting ataxin-2 could represent a broadly effective therapeutic strategy, as nearly all ALS patients have TDP-43 toxic aggregation in their neurons.
According to Becker, the team’s next step is to test whether ASOs or other protein-blocking treatments can reverse symptoms in mice in which the disease already has developed.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?